HS1

General Information


DRACP ID  DRACP01042

Peptide Name   HS1

Sequence  CGAISLAPKAQIKES

Sequence Length  15

UniProt ID  Q15116 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Cancer targeted peptides



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
CT26 Mouse colon adenocarcinoma Carcinoma IC50=19.2±2.3 µM MTT assay 24, 48, 72h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  programmed cell death protein 1

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01042

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C65H114N18O21S

Absent amino acids  DFHMNRTVWY

Common amino acids  A

Mass  176570

Pl  8.54

Basic residues  2

Acidic residues  1

Hydrophobic residues  6

Net charge  1

Boman Index  -784

Hydrophobicity  15.33

Aliphatic Index  98

Half Life 
  Mammalian: 1.2 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  4

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 33360579

Title  Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy

Doi 10.1016/j.bmc.2020.115951

Year  2021

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.